Evidence map›Paper›PMID 39496425›Full record

ReviewInfluenza and other respiratory viruses2024

Inno4Vac Workshop Report Part 1: Controlled Human Influenza Virus Infection Model (CHIVIM) Strain Selection and Immune Assays for CHIVIM Studies, November 2021, MHRA, UK.

Joanna Waldock, Rebecca J Cox, Christopher Chiu, Kanta Subbarao, Adrian Wildfire, Wendy Barclay, Puck B van Kasteren, John McCauley, Colin A Russell, Derek Smith and 3 more

Registry-linked trialAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Influenza and other respiratory viruses, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07063849 (A Pilot Study of the Effects of Pre-Existing Immunity on Influenza A/Texas/71/2017), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07063849 phase1active not recruitingnot on this mapstarted 2025, after this paper: background citation

A Pilot Study of the Effects of Pre-Existing Immunity on Influenza A/Texas/71/2017 (H3N2) Virus Shedding After Human Challenge in Healthy Participants

TypeinterventionalSponsorDaniel Hoft, MD, PhDRan2025 to 2026Enrolled12ConditionsInfluenzaArmsA/Texas
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Future Goals and Long-term Vision of the Infectious Diseases Clinical Research Consortium/Vaccine and Treatment Evaluation Unit Network.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Joanna WaldockInfluenza Resource Centre, Vaccines, Science Research & Innovation, Medicines and Healthcare Products Regulatory Agency, Potters Bar, UK.
Rebecca J CoxInfluenza Centre, Department of Clinical Sciences, University of Bergen, Bergen, Norway.
Christopher ChiuDepartment of Infectious Disease, Imperial College London, London, UK.
Kanta SubbaraoWHO Collaborating Centre for Reference and Research on Influenza and Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
Adrian WildfireCEO, CHIMunomics, Surrey, UK.
Wendy BarclayDepartment of Infectious Disease, Imperial College London, London, UK.
Puck B van KasterenCentre for Immunology of Infectious Diseases and Vaccines (IIV), National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.
John McCauleyWorld-wide Influenza Centre, Francis Crick Institute, London, UK.
Colin A RussellAmsterdam University Medical Centres, University of Amsterdam, Amsterdam, The Netherlands.
Derek SmithCentre for Pathogen Evolution, Infectious Diseases Research Centre, Department of Zoology, University of Cambridge, Cambridge, UK.
Ryan S ThwaitesNational Heart and Lung Institute, Imperial College London, London, UK.
John S TregoningDepartment of Infectious Disease, Imperial College London, London, UK.
Othmar G EngelhardtInfluenza Resource Centre, Vaccines, Science Research & Innovation, Medicines and Healthcare Products Regulatory Agency, Potters Bar, UK.

Funding

Innovative Medicines Initiative 101007799
6 · The paper itself

Abstract

Controlled human infection models (CHIMs) are a critical tool for the understanding of infectious disease progression, characterising immune responses to infection and rapid assessment of vaccines or drug treatments. There is increasing interest in using CHIMs for vaccine development and an obvious need for widely available and fit-for-purpose challenge agents. Inno4Vac is a large European consortium working towards accelerating and de-risking the development of new vaccines, including the development of CHIMs for influenza, respiratory syncytial virus and Clostridioides difficile. This report (in two parts) summarises a workshop held at the MHRA in 2021, focused on how to select CHIM candidate strains of influenza and respiratory syncytial virus (RSV) based on desirable virus characteristics and which immune assays would provide relevant information for assessing pre-existing and post-infection immune responses and defining correlates of protection. This manuscript (Part 1) summarises presentations and discussions centred around influenza CHIMs and immune assays (a second manuscript summarises RSV CHIM and immune assays: Inno4Vac workshop report Part 2: RSV CHIM strain selection and immune assays for RSV CHIM studies, November 2021, MHRA, UK).

Indexed as

Influenza, HumanAnimalsHumansInfluenza VaccinesRespiratory Syncytial Virus InfectionsUnited KingdomVaccine DevelopmentInfluenza Vaccinescontrolled human infection model (CHIM)controlled human influenza virus infection model (CHIVIM)correlates of protectionimmune assaysinfluenza viruses

Identifiers

PMID39496425
PMCPMC11534430

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.